Group 1 - The new model floating management fee funds are steadily advancing, with the first batch demonstrating significant effects, leading to the launch of a second batch of funds that have already attracted over 1.2 billion yuan in subscriptions on their first day [1][3] - The first batch of 26 new model floating management fee funds has seen a rapid increase in stock positions, with 22 funds achieving positive returns since their establishment, and several funds reporting returns exceeding 6% [2][1] - The cautious approach of the first batch of funds, which have not yet opened for regular subscriptions and redemptions, reflects a strategy to stabilize fund sizes and encourage long-term investment from investors [2][1] Group 2 - The second batch of funds has notable design features, including a focus on Hong Kong stock allocations and detailed performance benchmarks that incorporate relevant indices [3][4] - Specific performance benchmarks for the new funds include combinations of various indices, such as the CSI 800 Index and the Hong Kong Stock Connect Composite Index, indicating a strategic approach to performance measurement [3][4] - Some funds have introduced innovative features like "quarterly distribution upon meeting targets," allowing investors to receive cash dividends without redeeming their shares, enhancing the comfort and satisfaction of long-term holding [4][3]

Core Viewpoint - The recent launch of new floating fee rate funds by major public fund companies indicates a growing trend in the market, with a focus on innovative investment strategies and enhanced investor experience [2][8]. Fund Launch and Features - Three new funds have been launched: E Fund Value Return Mixed, China Europe Core Select Mixed, and CCB Medical Innovation Stock, with subscription deadlines on August 20, August 15, and August 22 respectively [2]. - CCB Medical Innovation Stock has a fundraising cap of 3 billion yuan, while the other two funds do not have a limit [2]. - All three funds can invest in Hong Kong stocks, allowing for A+H share market allocation, with a maximum of 50% of stock assets in Hong Kong Stock Connect [2]. Innovative Dividend Mechanism - The China Europe Core Select Mixed fund has introduced a "quarterly dividend upon meeting standards" clause, allowing investors to receive cash dividends without redeeming their shares if the profit per share exceeds 0.01 yuan [3][4]. - This mechanism aims to enhance the holding experience for investors, although it is emphasized that dividends do not directly correlate with the fund's management quality [4]. Performance Benchmark Design - Each fund has a clearly defined performance benchmark reflecting its investment strategy: - E Fund Value Return Mixed targets a combination of indices including 55% from the CSI 800 Index and 20% from the CSI Hong Kong Stock Connect Composite Index [5]. - China Europe Core Select Mixed focuses primarily on the CSI 800 Index with an 80% weight [5]. - CCB Medical Innovation Stock emphasizes industry attributes with 70% from the CSI Medical and Health Index [5][6]. Fee Structure - All three funds adopt a "benchmark + floating" fee management model, with a base management fee of 1.2% [7]. - The fee structure includes incentives for performance, with higher fees applicable when returns exceed the benchmark and reduced fees when underperforming [7]. - This floating mechanism is designed to protect investors, only applying to those who hold their investments for over a year [7]. Market Expansion and Policy Influence - The rapid expansion of floating fee rate funds is driven by clear regulatory guidance, with the China Securities Regulatory Commission mandating that such products should constitute at least 60% of the issuance from leading institutions [8]. - The first batch of 26 floating fee rate funds was quickly approved and launched, raising a total of 25.9 billion yuan by July 21, significantly higher than the average for active equity funds [8]. - The introduction of CCB Medical Innovation Stock marks a strategic expansion into sectors like healthcare and high-end manufacturing, indicating a trend towards more innovative product offerings [9].